Isolation and Antibacterial Activity Test of Seagrass Epiphytic Symbiont Bacteria Thalassia hemprichii from Bahowo Waters, North Sulawesi

Seagrass is a higher plant and has the ability to produce bioactive compounds such as antibacterial. Seagrass is also a host to a variety of bacteria. Bacteria that live in the host will produce the same compounds as the host's body. The utilization of symbiotic bacteria with seagrasses as producers of bioactive compounds such as antibacterial can be used as a solution to reduce excessive seagrass uptake in nature. On the other hand, bacteria have the advantage of being fast and easy to grow and can be mass-produced and more economical. This study aims to isolate and test the antibacterial activity of the epiphytic bacteria of seagrass symbionts. Epiphytic bacteria of seagrass symbionts were grown on Nutrient Agar media directly in the field and bacterial isolation was carried out based on the morphological characteristics of the bacterial isolates. The antibacterial activity test was carried out using the disc method with the test bacteria Stapylococcus aureus, Streptococcus mutans, Escherichia coli, Salmonella thypi, and antibiotics as positive controls. The ability of bacteria to produce antibacterial was indicated by the formation of an inhibition zone around the paper disc containing the epiphytic bacteria of the seagrass symbiont T. hemprichii. A total of 3 isolates of epiphytic bacteria were isolated from T. hemprichii seagrass from Bahowo Waters, Tongkaina Village, Bunaken District, these isolates are namely Epifit 1, Epiphyte 2, and Epiphyte 3. Epiphyte 2 isolate had antibacterial activity against S. mutans, S. aureus, and S. thypi test bacteria, Epiphyte 3 isolate had antibacterial activity against S. mutans, and S. thypi test bacteria.Key words: Bacteria; Antibacterial; T. hemprichii; symbionts; BahowoAbstrakLamun merupakan tumbuhan tingkat tinggi dan memiliki kemampuan menghasilkan senyawa  bioaktif seperti antibakteri. Lamun juga merupakan tempat hidup atau inang dari berbagai bakteri. Bakteri yang hidup pada inang akan menghasilkan senyawa yang sama dengan tubuh inangnya. Pemanfaatan bakteri yang bersimbiosis dengan lamun sebagai produsen senyawa bioaktif seperti antibakteri dapat dijadikan sebagai solusi dalam mengurangi pengambilan lamun yang berlebihan di alam. Dilain pihak, bakteri memiliki keunggulan karena pertumbuhan bakteri yang cepat dan mudah tumbuh, dapat diproduksi secara massal dan lebih ekonomis. Penelitian ini bertujuan untuk mengisolasi dan menguji aktivitas antibakteri dari bakteri epifit simbion lamun T. hemprichii dari Perairan Bahowo.  Bakteri epifit simbion lamun ditumbuhkan pada media NA secara langsung di lapangan dan isolasi bakteri dilaksanakan berdasarkan karateristik morfologi isolat bakteri. Uji aktivitas bakteri dilakukan menggunakan metode cakram dengan bakteri uji S. aureus, S. mutans, E. coli, dan S. thypi dan antibiotik sebagai kontrol positif. Kemampuan bakteri menghasilkan antibakteri ditandai dengan terbentuknya zona hambat disekitar kertas cakram yang mengandung bakkteri epifit simbion lamun T. hemprichii.  Sebanyak 3 isolat bakteri epifit berhasil diisolasi pada lamun T. hemprichii dari Perairan Bahowo, Kelurahan Tongkaina, Kecamatan Bunaken yaitu Epifit 1, Epifit 2, dan Epifit 3. Isolat epifit 3 memiliki aktivitas antibakteri terhadap bakteri uji S. thypi, isolat Epifit 2 terhadap bakteri uji S. mutans, S. aureus, dan S. thypi, isolat Epifit 3 terhadap bakteri uji S. mutans, dan S. thypi.Kata kunci: Bakteri; Antibakteri; T. hemprichii; Simbion; Bahow

Short-Term Pain and Long-Term Gain: Using Phased-In Minimum Size Limits to Rebuild Stocks-the Pacific Bluefin Tuna Example

Like many stocks, the Pacific Bluefin Tuna Thunnus orientalis has been considerably depleted. High exploitation rates on very young fish have reduced the spawning stock biomass (SSB) to 2.6% of the unexploited level. We provide a framework for exploring potential benefits of minimum size regulations as a mechanism for rebuilding stocks, and we illustrate the approach using simulations patterned after Pacific Bluefin Tuna dynamics. We attempt to mitigate short-term losses in yield by considering a phased-in management strategy. With this approach, the minimum size limit (MSL) is gradually increased as biomass rebuilds, giving fishing communities time to adjust to new restrictions. We estimated short- and long-term effects of different MSLs on yield and biomass by using data from the 2016 assessment. A variety of scenarios was considered for growth compensation, discard mortality, and interest rates. The long-term value of the fishery was maximized by setting an MSL of 92 cm FL, which resulted in a 70% loss in yield during the first year (short-term pain). By implementing the MSL in two phases (64 cm FL in year 1; 92 cm FL in subsequent years), the long-term value of the fishery was maintained, and the short-term pain was reduced to a maximum 46% loss in yield during any 1 year. Under a three-phase implementation (55 cm FL in year 1; 77 cm FL in year 2; and 92 cm FL in subsequent years), the short-term pain was further reduced to a maximum loss of 30% during any 1 year. With no discard mortality, long-term yield increased by 165% and SSB increased 13-fold (to 33% of virgin SSB), regardless of the number of phases used. Long-term benefits were quickly diminished with increasing discard mortality. This simulation approach is widely applicable to cases where minimum size changes are contemplated; for Pacific Bluefin Tuna, our simulations demonstrate that size limits should be considered

Influences of obese (ob/ob) and diabetes (db/db) genotype mutations on lumber vertebral radiological and morphometric indices: Skeletal deformation associated with dysregulated systemic glucometabolism

BACKGROUND: Both diabetes and obesity syndromes are recognized to promote lumbar vertebral instability, premature osteodegeneration, exacerbate progressive osteoporosis and increase the propensity towards vertebral degeneration, instability and deformation in humans. METHODS: The influences of single-gene missense mutations, expressing either diabetes (db/db) or obese (ob/ob) metabolic syndromes on vertebral maturation and development in C57BL/KsJ mice were evaluated by radiological and macro-morphometric analysis of the resulting variances in osteodevelopment indices relative to control parameters between 8 and 16 weeks of age (syndrome onset @ 4 weeks), and the influences of low-dose 17-B-estradiol therapy on vertebral growth expression evaluated. RESULTS: Associated with the indicative genotypic obesity and hyper-glycemic/-insulinemic states, both db/db and ob/ob mutants demonstrated a significant (P ≤ 0.05) elongation of total lumbar vertebrae column (VC) regional length, and individual lumbar vertebrae (LV1-5) lengths, relative to control VC and LV parameters. In contrast, LV1-5 width indices were suppressed in db/db and ob/ob mutants relative to control LV growth rates. Between 8 and 16 weeks of age, the suppressed LV1-5 width indices were sustained in both genotype mutant groups relative to control osteomaturation rates. The severity of LV1-5 width osteosuppression correlated with the severe systemic hyperglycemic and hypertriglyceridemic conditions sustained in ob/ob and db/db mutants. Low-dose 17-B-estradiol therapy (E2-HRx: 1.0 ug/ 0.1 ml oil s.c/3.5 days), initiated at 4 weeks of age (i.e., initial onset phase of db/db and ob/ob expressions) re-established control LV 1–5 width indices without influencing VC or LV lengths in db/db groups. CONCLUSION: These data demonstrate that the abnormal systemic endometabolic states associated with the expression of db/db and ob/ob genomutation syndromes suppress LV 1–5 width osteomaturation rates, but enhanced development related VC and LV length expression, relative to control indices in a progressive manner similar to recognized human metabolic syndrome conditions. Therapeutic E2 modulation of the hyperglycemic component of diabetes-obesity syndrome protected the regional LV from the mutation-induced osteopenic width-growth suppression. These data suggest that these genotype mutation models may prove valuable for the evaluation of therapeutic methodologies suitable for the treatment of human diabetes- or obesity-influenced, LV degeneration-linked human conditions, which demonstrate amelioration from conventional replacement therapies following diagnosis of systemic syndrome-induced LV osteomaturation-associated deformations

Control of mechanical pain hypersensitivity in mice through ligand-targeted photoablation of TrkB-positive sensory neurons

Mechanical allodynia is a major symptom of neuropathic pain whereby innocuous touch evokes severe pain. Here we identify a population of peripheral sensory neurons expressing TrkB that are both necessary and sufficient for producing pain from light touch after nerve injury in mice. Mice in which TrkB-Cre-expressing neurons are ablated are less sensitive to the lightest touch under basal conditions, and fail to develop mechanical allodynia in a model of neuropathic pain. Moreover, selective optogenetic activation of these neurons after nerve injury evokes marked nociceptive behavior. Using a phototherapeutic approach based upon BDNF, the ligand for TrkB, we perform molecule-guided laser ablation of these neurons and achieve long-term retraction of TrkB-positive neurons from the skin and pronounced reversal of mechanical allodynia across multiple types of neuropathic pain. Thus we identify the peripheral neurons which transmit pain from light touch and uncover a novel pharmacological strategy for its treatment

Diabetes-Specific Nutrition Algorithm: A Transcultural Program to Optimize Diabetes and Prediabetes Care

Type 2 diabetes (T2D) and prediabetes have a major global impact through high disease prevalence, significant downstream pathophysiologic effects, and enormous financial liabilities. To mitigate this disease burden, interventions of proven effectiveness must be used. Evidence shows that nutrition therapy improves glycemic control and reduces the risks of diabetes and its complications. Accordingly, diabetes-specific nutrition therapy should be incorporated into comprehensive patient management programs. Evidence-based recommendations for healthy lifestyles that include healthy eating can be found in clinical practice guidelines (CPGs) from professional medical organizations. To enable broad implementation of these guidelines, recommendations must be reconstructed to account for cultural differences in lifestyle, food availability, and genetic factors. To begin, published CPGs and relevant medical literature were reviewed and evidence ratings applied according to established protocols for guidelines. From this information, an algorithm for the nutritional management of people with T2D and prediabetes was created. Subsequently, algorithm nodes were populated with transcultural attributes to guide decisions. The resultant transcultural diabetes-specific nutrition algorithm (tDNA) was simplified and optimized for global implementation and validation according to current standards for CPG development and cultural adaptation. Thus, the tDNA is a tool to facilitate the delivery of nutrition therapy to patients with T2D and prediabetes in a variety of cultures and geographic locations. It is anticipated that this novel approach can reduce the burden of diabetes, improve quality of life, and save lives. The specific Southeast Asian and Asian Indian tDNA versions can be found in companion articles in this issue of Current Diabetes Reports